Mr. Wei Fu is an Executive Chairman at NovaBridge Biosciences, a Chief Executive Officer & Managing Partner at C-Bridge Capital Investment Management Ltd., a Chief Executive Officer at CBC Group (Singapore) Pte. Ltd., a Chairman at AffaMed Therapeutics Co., Ltd. and a Chief Executive Officer at CBC Group Co., Ltd. He is on the Board of Directors at Everest Medicines Ltd., Affamed Therapeutics (Us), Inc., Ascletis Biopharmaceutical (Hangzhou) Co. Ltd., C-Bridge Capital GP IV Ltd., Everest Medicines (Singapore) Pte Ltd., Everest Medicines II BVI Ltd., Everest Medicines II HK Ltd., Everest Medicines II Ltd., Everonc Medicines Ltd. and Everonc Medicines, Inc. Mr. Fu was previously employed as a General Manager-Investment Department by Far East Horizon Ltd., a Head-Beijing Officer by Themes Investment Management Ltd., an Associate Director-Private Equity Department by Standard Chartered Business Consulting Beijing Co. Ltd., a Non-Executive Director by Ascletis Pharma, Inc., and a Non-Executive Director by Hugel, Inc. He received his undergraduate degree from Nanyang Technological University.
Wei Fu
Mr. Wei Fu is an Executive Chairman at NovaBridge Biosciences, a Chief Executive Officer & Managing Partner at C-Bridge Capital Investment Management Ltd., a Chief Executive Officer at CBC Group (Singapore) Pte. Ltd., a Chairman at AffaMed Therapeutics Co., Ltd. and a Chief Executive Officer at CBC Group Co., Ltd. He is on the Board of Directors at Everest Medicines Ltd., Affamed Therapeutics (Us), Inc., Ascletis Biopharmaceutical (Hangzhou) Co. Ltd., C-Bridge Capital GP IV Ltd., Everest Medicines (Singapore) Pte Ltd., Everest Medicines II BVI Ltd., Everest Medicines II HK Ltd., Everest Medicines II Ltd., Everonc Medicines Ltd. and Everonc Medicines, Inc. Mr. Fu was previously employed as a General Manager-Investment Department by Far East Horizon Ltd., a Head-Beijing Officer by Themes Investment Management Ltd., an Associate Director-Private Equity Department by Standard Chartered Business Consulting Beijing Co. Ltd., a Non-Executive Director by Ascletis Pharma, Inc., and a Non-Executive Director by Hugel, Inc. He received his undergraduate degree from Nanyang Technological University.
Chun Kwok Au
Chun Kwok Au is the founder of Gt Healthcare Group, founded in 2015, serving as Managing Partner. Current jobs include Independent Non-Executive Director at CSPC Pharmaceutical Group Ltd. since 2021, Independent Director at NovaBridge Biosciences since 2020, Member of The American Institute of Certified Public Accountants, and Associate Member of The Hong Kong Institute of Financial Analysts & Professional. Former jobs include Independent Non-Executive Director at Simcere Pharmaceutical Group Ltd. in 2013, Independent Director at China Nepstar Chain Drugstore Ltd. from 2013 to 2016, Independent Non-Executive Director at AbelZeta Pharma, Inc., Director at JAFCO Investment (Asia Pacific) Ltd. from 2008 to 2010, Director at Morningside Group (Holdings) Ltd. from 2000 to 2005, Head-Asia Healthcare Investment Banking Group at Deutsche Bank AG from 2011 to 2012, and Partner at Ally Bridge Group HK Ltd. Education includes an undergraduate degree from The Chinese University of Hong Kong in 1995 and a graduate degree from Columbia Business School in 2007.
Chia Hung Yang
Mr. Chia Hung Yang is an Independent Director at Smart Share Global Ltd., a Chief Financial Officer at Sunrate Holdings Ltd., an Independent Director at UP Fintech Holding Ltd., an Independent Director at Tongcheng Travel Holdings Ltd., an Independent Director at iQIYI, Inc., a Chief Financial Officer at Beijing Tendcloud Tianxia Technology Co., Ltd., a Chief Financial Officer at Talkingdata Group Holding Ltd., an Independent Director at NovaBridge Biosciences, a Chief Financial Officer & Director at EHang Holdings Ltd., a Chief Financial Officer at Nanjing Tuniu Technology Co. Ltd. and an Independent Director at InnoLight Technology Corp. He is on the Board of Directors at Smart Share Global Ltd., UP Fintech Holding Ltd., Tongcheng Travel Holdings Ltd., iQIYI, Inc., NovaBridge Biosciences, EHang Holdings Ltd., Vance International, Inc. and InnoLight Technology Corp. Mr. Yang was previously employed as an Independent Director by DDC Enterprise Ltd., a Co-Founder by Xiaoheiyu Technology Co., Ltd., an Independent Director by 51Talk Online Education Group, an Independent Non-Executive Director by Leyou Technologies Holdings Ltd., an Independent Director by AirNet Technology, Inc., a Chief Financial Officer by Tuniu Corp., a Chief Financial Officer by Beijing Dandang Information Technology Co., Ltd., an Independent Director by IFM Investments Ltd., a Chief Financial Officer by AirNet Technology, Inc., a Chief Executive Officer by Rock Mobile Corp., a Chief Financial Officer-Asia Pacific Region by Cellstar (Asia) Corp., an Executive Director by Goldman Sachs (Asia) LLC, an Executive Director by Goldman Sachs (Asia) LLC (South Korea), a Chief Investment Officer by Sherwood, Inc., a Vice President by Lehman Brothers Asia Ltd. (Hong Kong), an Associate by Morgan Stanley Asia Ltd., and a Chief Financial Officer by AIRMEDIA, Inc. He received his undergraduate degree from Fu Jen Catholic University and an MBA from the University of California, Los Angeles.
Xi-Yong Fu
Xi-Yong Fu was the founder of RVAC Medicines Pte Ltd., founded in 2021, and held the title of Chief Executive Officer from 2021 to 2024. Dr. Fu is also the founder of RVAC Medicines.. Dr. Fu is Chief Executive Officer & Director at NovaBridge Biosciences since 2024. Dr. Fu was Chief Executive Officer at Abio-X Holdings, Inc. Dr. Fu earned an MBA from the University of Pennsylvania and a doctorate from The Ohio State University.
Robert A. Lenz
Robert A. Lenz is currently Co-Managing Director at Lenz, K?mper GmbH & Co. KG. He is also an Independent Director at LB Pharmaceuticals, Inc. starting in 2026 and an Independent Director at NovaBridge Biosciences starting in 2025. Formerly, Dr. Lenz was Senior Vice President & Head-Global Development at Amgen, Inc. and Head-Research & Development at Neumora Therapeutics, Inc. Dr. Lenz earned a doctorate from the University of Maryland and completed undergraduate studies at Dickinson College.
Xin Liu
Xin Liu is currently an Independent Director at NovaBridge Biosciences, a position started in 2025. Ms. Liu completed undergraduate education at the University of Washington and holds graduate degrees from the Massachusetts Institute of Technology and Harrisburg University of Science & Technology.
Sean Wuxiong Cao
Sean Wuxiong Cao was the founder of Everest Medicines Ltd., founded in 2017, where the title held was CEO from 2017 to 2020. Dr. Cao is also the founder of Abio-X Holdings, Inc... Current jobs include Managing Director at CBC Group (Singapore) Pte. Ltd. since 2016, Director & Chief Business Development Officer at NovaBridge Biosciences starting in 2025, and Director at NiKang Therapeutics, Inc. Former jobs include Chief Executive Officer & Director at ENSEM Therapeutics, Inc., Director at Aureon Biosciences, Inc. from 2009 to 2010, Manager-Product Development at Johnson & Johnson in 2008, Associate at New Leaf Venture Partners LLC from 2008 to 2009, and Senior Research Investigator at Sanofi-Aventis U.S. LLC from 2001 to 2004. Education includes an MBA from the University of Pennsylvania, a doctorate from Nankai University, and a doctorate from the University of Virginia conferred in 1990.
Ian Ying Woo
Ian Ying Woo is currently President, CFO & Executive Director at Everest Medicines Ltd. since 2022, and Executive Director at Everest Medicines (US) Ltd. and Everest Medicines II Ltd. Mr. Woo is also Director at NovaBridge Biosciences starting in 2025 and Operating Partner at CBC Group Co., Ltd. since 2019. Former roles include Managing Director at Lazard Frères & Co. LLC and Independent Director at Prenetics Global Ltd. Education includes an undergraduate degree from Tufts University in 1994, a graduate degree from the Graduate School of Arts & Sciences at Columbia University in 1998, and an MBA from Columbia Business School in 2003.
Emmett T. Cunningham
Emmett T. Cunningham founded Ophthalmology Innovation Summit in 2009, Placid0, Inc. in 2020, and Eyconis, Inc. in 2024, where he is working as Chairman from 2024. Dr. Cunningham also founded Pr3vent, Inc and Visara, Inc., where he is working as Executive Chairman. Dr. Cunningham also currently works at NovaBridge Biosciences, as Vice Chairman from 2026, California Pacific Medical Center, as Director-Uveitis Service, SFJ Pharmaceuticals, Inc., as Director, and various other companies. Dr. Cunningham also formerly worked at NewLink Genetics Corp., as Director, Restoration Robotics, Inc., as Independent Director from 2011 to 2018, Annexon, Inc., as Director from 2014 to 2021, and various other companies. Dr. Cunningham received his graduate degree in 1991 and doctorate degree in 1990 from The Johns Hopkins University, undergraduate degree in 1981 from Drexel University, and doctorate degree in 1989 from the University of California San Diego.
提供，免责声明：天汇财经、Factset及其他信息供应商努力确保所提供信息的准确性和可靠性，但对于其正确性或可靠性则不予担保，且对于因不正确或疏漏所造成的任何损失或损坏概不负责(无论是有关民事过失、合同或其他方面)。